---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-25-000017"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:40:11.615542+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xeris exceeds FY2024 revenue guidance with $203M; Q4 positive cash flow; Recorlev up 28% sequentially

## Summary
- Total FY2024 revenue expected at $203M, exceeding prior guidance of $198-202M (24% YoY growth).
- Q4 2024 revenue projected at $60M (35% YoY growth); company generated positive cash flow in Q4.
- Recorlev net revenue in Q4 anticipated to increase ~$5M or 28% sequentially, with record new starts.
- Year-end cash, equivalents, and short-term investments expected to be over $71M.
- Amgen terminated XeriJect license per portfolio assessment; no material impact on Xeris outlook.

## SEC filing metadata
- accession: 0001867096-25-000017
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000017/0001867096-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000017/xers-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-25-000017
- JSON: https://secwatch.observer/filing/0001867096-25-000017.json
- Plain text: https://secwatch.observer/filing/0001867096-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.